Professional development and education
Timely communication of evolving safety information is a critical element in the ability of practitioners to provide the best care for patients with rheumatic diseases. At this session, the panel will discuss the FDA’s approach to ensuring the availability of safe and effective drugs and highlight new initiatives at FDA. This session will provide an update on late-breaking or evolving topics in patient safety, including any relevant FDA analysis or response to these issues. In addition, case studies or examples of interesting regulatory issues or safety issues will be presented.